Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a high risk of developing diabetes. It also develops, manufactures, and distributes products in the enzyme-linked immunosorbent, western blot, and cytotoxicity assay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. Further, it offers Uni-Gold S. pneumoniae, Uni-Gold Legionella, Uni-Gold C. difficile, and Uni-Gold Syphilis products. The company sells its products through its direct sales force in the United States; and a network of independent distributors and strategic partners internationally. Its customers include public health facilities, hospitals, and other outreach facilities, as well as clinical and reference laboratories. Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TRIB
CUSIPN/A
Phone353-1276-9800
Debt
Debt-to-Equity Ratio1.45
Current Ratio5.03
Quick Ratio3.49
Price-To-Earnings
Trailing P/E Ratio18.88
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$99.14 million
Price / Sales1.04
Cash Flow$0.3129 per share
Price / Cash15.69
Book Value$2.71 per share
Price / Book1.81
Profitability
EPS (Most Recent Fiscal Year)$0.26
Net Income$-40,270,000.00
Net Margins-41.38%
Return on Equity3.26%
Return on Assets1.28%
Miscellaneous
Employees582
Outstanding Shares20,930,000
Trinity Biotech (NASDAQ:TRIB) Frequently Asked Questions
What is Trinity Biotech's stock symbol?
Trinity Biotech trades on the NASDAQ under the ticker symbol "TRIB."
How were Trinity Biotech's earnings last quarter?
Trinity Biotech plc (NASDAQ:TRIB) posted its quarterly earnings data on Tuesday, May, 1st. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.05 by $0.03. The company earned $23.80 million during the quarter. Trinity Biotech had a positive return on equity of 3.26% and a negative net margin of 41.38%. View Trinity Biotech's Earnings History.
When is Trinity Biotech's next earnings date?
Who are some of Trinity Biotech's key competitors?
Some companies that are related to Trinity Biotech include Oxford Immunotec Global (OXFD), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Celldex Therapeutics (CLDX), Vermillion (VRML), ImmuCell (ICCC), Akers Biosciences (AKER), Arca Biopharma (ABIO), GeneNews (GNWSF), Achieve Life Sciences (ACHV), Fluoropharma Medical (FPMI), BG Medicine (BGMD), Response Genetics (RGDXQ) and Palatin Technologies (PTN).
Who are Trinity Biotech's key executives?
Trinity Biotech's management team includes the folowing people:
- Mr. Ronan O'Caoimh, Co-Founder, Chairman and Chief Exec. Officer (Age 62)
- Mr. Kevin Tansley, Chief Financial Officer, Sec. and Director (Age 47)
- Dr. James Walsh Ph.D., Bus. Devel. Director and Exec. Director (Age 60)
Has Trinity Biotech been receiving favorable news coverage?
Media coverage about TRIB stock has trended positive recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Trinity Biotech earned a coverage optimism score of 0.27 on Accern's scale. They also assigned news articles about the company an impact score of 44.75 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Trinity Biotech's major shareholders?
Trinity Biotech's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Russell Investments Group Ltd. (8.98%), Lapides Asset Management LLC (5.04%), Heartland Advisors Inc. (5.62%), First Wilshire Securities Management Inc. (4.78%), 22NW LP (4.50%) and Boston Partners (3.54%). View Institutional Ownership Trends for Trinity Biotech.
Which institutional investors are selling Trinity Biotech stock?
TRIB stock was sold by a variety of institutional investors in the last quarter, including Boston Partners, Heartland Advisors Inc., Millennium Management LLC, First Wilshire Securities Management Inc. and US Bancorp DE. View Insider Buying and Selling for Trinity Biotech.
Which institutional investors are buying Trinity Biotech stock?
How do I buy shares of Trinity Biotech?
Shares of TRIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Trinity Biotech's stock price today?
One share of TRIB stock can currently be purchased for approximately $4.91.
How big of a company is Trinity Biotech?
Trinity Biotech has a market capitalization of $102.34 million and generates $99.14 million in revenue each year. The company earns $-40,270,000.00 in net income (profit) each year or $0.26 on an earnings per share basis. Trinity Biotech employs 582 workers across the globe.
How can I contact Trinity Biotech?
Trinity Biotech's mailing address is IDA BUSINESS PARK BRAY, WICKLOW L2, . The company can be reached via phone at 353-1276-9800 or via email at [email protected]
MarketBeat Community Rating for Trinity Biotech (TRIB)
MarketBeat's community ratings are surveys of what our community members think about Trinity Biotech and other stocks. Vote "Outperform" if you believe TRIB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRIB will underperform the S&P 500 over the long term. You may vote once every thirty days.
